EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Percutaneous Microaxial Ventricular Assist Device Versus Intra‐Aortic Balloon Pump for Nonacute Myocardial Infarction Cardiogenic Shock

Atsuyuki Watanabe iD, Yoshihisa Miyamoto iD, Hiroki Ueyama, Hiroshi Gotanda iD, Yusuke Tsugawa iD, Toshiki Kuno iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.034645 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Atsuyuki Watanabe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Mount Sinai Beth Israel Icahn School of Medicine at Mount Sinai New York NY. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Intra-Aortic Balloon Pumping, Heart-Assist Devices, Myocardial Infarction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence on the comparative outcomes following percutaneous microaxial ventricular assist devices (pVAD) versus intra‐aortic balloon pump for nonacute myocardial infarction cardiogenic shock is limited. Methods and Results We included 704 and 2140 Medicare fee‐for‐service beneficiaries aged 65 to 99 years treated with pVAD and intra‐aortic balloon pump, respectively, for nonacute myocardial infarction cardiogenic shock from 2016 to 2020. Patients treated using pVAD compared with those treated using intra‐aortic balloon pump were more likely to be concurrently treated with mechanical ventilation, renal replacement therapy, and blood transfusions. We computed propensity scores for undergoing pVAD using patient‐ and hospital‐level factors and performed a matching weight analysis. The use of pVAD was associated with higher 30‐day mortality (adjusted odds ratio, 1.92 [95% CI, 1.59–2.33]) but not associated with in‐hospital bleeding (adjusted odds ratio, 1.00 [95% CI, 0.81–1.24]), stroke (adjusted odds ratio, 0.91 [95% CI, 0.56–1.47]), sepsis (OR, 0.91 [95% CI, 0.64–1.28]), and length of hospital stay (adjusted mean difference, +0.4 days [95% CI, −1.4 to +2.3]). A quasi‐experimental instrumental variable analysis using the cross‐sectional institutional practice preferences showed similar patterns, though not statistically significant (adjusted odds ratio, 1.38; 95% CI, 0.28–6.89).

Conclusions

Our investigation using the national sample of Medicare beneficiaries showed that the use of pVAD compared with intra‐aortic balloon pump was associated with higher mortality in patients with nonacute myocardial infarction cardiogenic shock. Providers should be cautious about the use of pVAD for nonacute myocardial infarction cardiogenic shock, while adequately powered high‐quality randomized controlled trials are warranted to determine the clinical effects of pVAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shock, CardiogenicIntra-Aortic Balloon PumpingHeart-Assist DevicesMyocardial InfarctionHumansMaleAgedFemaleAged, 80 and overUnited StatesRetrospective StudiesTreatment OutcomeMedicare

Stichwörter der Autor:innen

Medicarecardiogenic shockendovascular proceduresheart‐assist devicemechanical circulatory support

Autor:innen und Institutionen

  • Department of Medicine Mount Sinai Beth Israel Icahn School of Medicine at Mount Sinai New York NY.
  • Division of Nephrology and Endocrinology The University of Tokyo Tokyo Japan.
  • Division of Cardiology Emory University School of Medicine Atlanta GA.
  • Division of General Internal Medicine Cedars-Sinai Medical Center Los Angeles CA.
  • Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at The University of California, Los Angeles Los Angeles CA.
  • Department of Health Policy and Management UCLA Fielding School of Public Health, Los Angeles Los Angeles CA.

ORCID-Profile: Atsuyuki Watanabe, Yoshihisa Miyamoto, Hiroshi Gotanda, Yusuke Tsugawa, Toshiki Kuno

Förderung

  • NIA NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Watanabe, A., Miyamoto, Y., Ueyama, H., Gotanda, H., Tsugawa, Y., & Kuno, T. (2024). Percutaneous Microaxial Ventricular Assist Device Versus Intra‐Aortic Balloon Pump for Nonacute Myocardial Infarction Cardiogenic Shock. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.034645

Vancouver

Watanabe A, Miyamoto Y, Ueyama H, Gotanda H, Tsugawa Y, Kuno T. Percutaneous Microaxial Ventricular Assist Device Versus Intra‐Aortic Balloon Pump for Nonacute Myocardial Infarction Cardiogenic Shock. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.034645

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Atsuyuki and Miyamoto, Yoshihisa and Ueyama, Hiroki and Gotanda, Hiroshi and Tsugawa, Yusuke and Kuno, Toshiki},
  title = {Percutaneous Microaxial Ventricular Assist Device Versus Intra‐Aortic Balloon Pump for Nonacute Myocardial Infarction Cardiogenic Shock},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.034645}
}
Kostenlos starten →